Analysis of immune and high‐risk biomarkers in patients with relapsed or refractory mantle cell lymphoma treated with glofitamab monotherapy.

Autor: Pham*, T. H., Leung*, W., Hamidi, H., Dickinson, M., Morschhauser, F., Carlo‐Stella, C., Humphrey, K., Mulvihill, E., Lundberg, L., Filezac de L'Etang, A., Qayum, N., Bottos, A., Phillips, T.
Předmět:
Zdroj: Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p486-488, 3p
Abstrakt: Bulk RNA-sequencing analysis from tumor biopsies included gene set variation analysis and xCell cell type enrichment. Analysis of immune and high-risk biomarkers in patients with relapsed or refractory mantle cell lymphoma treated with glofitamab monotherapy Additionally, gene expression analysis of BL tumors ( I n i = 27) showed a trend towards higher T-cell signatures and lower tumor proliferation-related signatures, in responders versus non-responders. [Extracted from the article]
Databáze: Complementary Index